Zhejiang Gene Stem Cell Biotech

Zhejiang Gene Stem Cell Biotech (ZSCB) is a high-tech biomedical company based in Zhejiang, China, specializing in the commercialization of stem cell technology and regenerative medicine. The company focuses on the development of cell therapies, genetic engineering services, and the storage of biological resources such as umbilical cord and placenta-derived mesenchymal stem cells. ZSCB is notably recognized for its clinical research into treating unresponsive thin endometrium caused by Asherman syndrome using umbilical cord mesenchymal stem cells (UC-MSCs) delivered via collagen scaffolds. In addition to its therapeutic pipeline, the company provides commercial stem cell storage and genetic testing services in collaboration with major regional hospitals. ZSCB operates through strategic partnerships with academic institutions like Sir Run Run Shaw Hospital and is partially owned by the investment group Pan Hong Holdings.